GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Ainos AIMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.60

-14.04%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ainos

From its filings with the US Securities and Exchange Commission

SEC filings

Ainos is based in Houston, Texas and is incorporated in Texas. Its shares trade on Nasdaq under the ticker AIMD. The SEC classifies its business as computer peripheral equipment, nec. In the fiscal year to 31 December 2025, it reported revenue of $124,157 and a net loss of $14.8m. At that date it held total assets of $20.9m and shareholders' equity of $7.6m.

In its own words

AI Nose to address this gap by translating complex scent signals into a structured, machine-readable data format.

Relationships. We work with third parties to support the commercialization of our products across different markets and applications.

31, 2025, our VELDONA FCGA candidate, a veterinary application of our VELDONA drug, has not been approved to sell by TFDA.

Failure to comply with applicable regulations could result in fines, suspension of operations, or other regulatory actions.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Aug 1996
Employees
43
Website
ainos.com ↗
Head office
3050 POST OAK BLVD,, HOUSTON, TX, 77056
Incorporated in
TX
Classification
Computer Peripheral Equipment, NEC
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Chun-Hsien TsaiChairman of the Board, President, Chief Executive Officer, since 2021$301,522
  • Mr. Hsin-Liang LeeChief Financial Officer$93,623
  • Ms. Ting-Chuan LeeDirector$84,067
  • Mr. Chung-Yi TsaiDirector$12,000
  • Mr. Chun-Jung TsaiDirector$81,372
  • Mr. Wen-Han ChangIndependent Director$20,500
  • Mr. Yao-Chung ChiangIndependent Director$16,000
  • Mr. Pao- Sheng WeiIndependent Director$22,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in the Health Care sector with a focus on Biotechnology.
  • Headquartered in San Diego, California with 43 employees.
  • Offers medical technologies including POCT testing and non-injectable interferon therapeutics.

Weaknesses

  • Limited employee count of 43 may restrict operational capacity.
  • IPO date of 1996-08-08 suggests a long history but potential outdated infrastructure.
  • Reliance on specific medical technologies may limit market diversification.

Opportunities

  • Growing demand for point-of-care testing solutions in healthcare.
  • Potential expansion of medical technology applications for various disease indications.
  • Increasing focus on non-invasive diagnostic tools like VOC POCT devices.

Threats

  • Competition in the biotechnology industry may impact market share.
  • Regulatory challenges for medical device commercialization.
  • Dependence on specific therapeutic technologies like interferon may pose risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.